Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 6/20 | 0.64 |
| ▸ | CTSB | P07858 | 4/20 | 0.64 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.55 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.54 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP3 | P08254 | 1/20 | 0.44 |
| ▸ | MMP7 | P09237 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3914487 | 0.88 | CAPN1 (0.62) | CAPN1CTSBADAM17LARS1SLC1A3 | |
| SCHEMBL3907752 | 0.88 | CAPN1 (0.49) | CAPN1CTSBADAM17LARS1SLC1A3 | |
| SCHEMBL27486757 | 0.84 | ADAM17 (0.55) | CAPN1CTSBADAM17LARS1SLC1A3 | |
| SCHEMBL6984103 | 0.84 | ADAM17 (0.55) | CAPN1CTSBADAM17LARS1SLC1A3 | |
| SCHEMBL3917869 | 0.83 | CAPN1 (0.54) | CAPN1CTSBSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3913553 | 0.82 | CAPN1 (0.66) | CAPN1CTSBSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6026500 | 0.82 | CAPN1 (0.66) | CAPN1CTSBSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL3905584 | 0.82 | MMP2 (0.54) | CAPN1CTSBSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL1907361 | 0.82 | CAPN1 (0.66) | CAPN1CTSBSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL5363846 | 0.82 | CAPN1 (0.66) | CAPN1CTSBSLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10147564-A | — | — | None | — | — | JP | disclosed |
| US-7572833-B2 | Drug composition comprising dipeptidyl aldehyde derivative | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2009-08-11 | — | — | US | disclosed |
| EP-1504760-B1 | Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy | SENJU PHARMA CO (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-7052714-B1 | Ophthalmic adhesive preparations for percutaneous adsorption | SENJU PHARMACEUTICAL CO., LTD (JP) | 2006-05-30 | — | — | US | disclosed |
| EP-1058553-B1 | PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS AND THERAPY OF DISEASES ASSOCIATED WITH OCULAR FUNDUS TISSUE CYTOPATHY | SENJU PHARMA CO (JP) | 2005-06-01 | — | — | EP | disclosed |
| EP-1504760-A1 | Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy | Senju Pharmaceutical Co., Ltd. (JP) | 2005-02-09 | — | — | EP | disclosed |
| EP-1064021-B1 | USE OF CYSTEINPROTEASE INHIBITORS FOR THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND TREATMENT OF BRAIN TISSUE IMPAIRMENT DUE TO HYPERTENSIVE ENCEPHALOPATHY OR ENCEPHALOTHLIPSIS. | SENJU PHARMA CO (JP) | 2004-09-08 | — | — | EP | disclosed |
| US-20040048929-A1 | Drug composition comprising dipeptidyl aldehyde derivative | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2004-03-11 | — | — | US | disclosed |
| EP-1334718-A1 | DRUG COMPOSITION COMPRISING DIPEPTYDYL ALDEHYDE DERIVATIVE | Senju Pharmaceutical Co., Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
| EP-0927716-B1 | Angiogenesis inhibitor | SENJU PHARMA CO (JP) | 2003-05-07 | — | — | EP | disclosed |
| US-6214800-B1 | ANGIOGENESIS INHIBITORS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2001-04-10 | — | — | US | disclosed |
| EP-1064021-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A CYSTEINE PROTEASE INHIBITOR FOR PROPHYLAXIS AND THERAPY OF BRAIN TISSUE IMPAIRMENT | Senju Pharmaceutical Co., Ltd. (JP) | 2001-01-03 | — | — | EP | disclosed |
| EP-1058553-A2 | PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS AND THERAPY OF DISEASES ASSOCIATED WITH OCULAR FUNDUS TISSUE CYTOPATHY | Senju Pharmaceutical Co., Ltd. (JP) | 2000-12-13 | — | — | EP | disclosed |
| US-6057290-A | ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS | SENJU PHARMACEUTICAL CO., LTD. (JP) | 2000-05-02 | — | — | US | disclosed |
| WO-1999048522-A1 | PHARMACEUTICAL COMPOSITION CONTAINING A CYSTEINE PROTEASE INHIBITOR FOR PROPHYLAXIS AND THERAPY OF BRAIN TISSUE IMPAIRMENT | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999044624-A2 | PHARMACEUTICAL COMPOSITION FOR PROPHYLAXIS AND THERAPY OF DISEASES ASSOCIATED WITH OCULAR FUNDUS TISSUE CYTOPATHY | SENJU PHARMACEUTICAL CO., LTD. (JP) | 1999-09-10 | — | — | WO | disclosed |
| EP-0928786-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0927716-A1 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1999-07-07 | — | — | EP | disclosed |
| JP-H10147564-A | PEPTIDYL ALDEHYDE DERIVATIVE AND ITS USE | SENJU PHARMACEUT CO LTD | 1998-06-02 | — | — | JP | disclosed |
| EP-0771565-A2 | Angiogenesis inhibitor | Senju Pharmaceutical Co., Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048929-A1 | Drug composition comprising dipeptidyl aldehyde derivative | DPP4, DPP3, DPP7 | CAPN1 2707/4885CTSB 1998/4885ADAM17 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.